Literature DB >> 17448881

Target coverage in image-guided stereotactic body radiotherapy of liver tumors.

Wouter Wunderink1, Alejandra Méndez Romero, Eliana M Vásquez Osorio, Hans C J de Boer, René P Brandwijk, Peter C Levendag, Ben J M Heijmen.   

Abstract

PURPOSE: To determine the effect of image-guided procedures (with computed tomography [CT] and electronic portal images before each treatment fraction) on target coverage in stereotactic body radiotherapy for liver patients using a stereotactic body frame (SBF) and abdominal compression. CT guidance was used to correct for day-to-day variations in the tumor's mean position in the SBF. METHODS AND MATERIALS: By retrospectively evaluating 57 treatment sessions, tumor coverage, as obtained with the clinically applied CT-guided protocol, was compared with that of alternative procedures. The internal target volume-plus (ITV(+)) was introduced to explicitly include uncertainties in tumor delineations resulting from CT-imaging artifacts caused by residual respiratory motion. Tumor coverage was defined as the volume overlap of the ITV(+), derived from a tumor delineated in a treatment CT scan, and the planning target volume. Patient stability in the SBF, after acquisition of the treatment CT scan, was evaluated by measuring the displacement of the bony anatomy in the electronic portal images relative to CT.
RESULTS: Application of our clinical protocol (with setup corrections following from manual measurements of the distances between the contours of the planning target volume and the daily clinical target volume in three orthogonal planes, multiple two-dimensional) increased the frequency of nearly full (> or = 99%) ITV(+) coverage to 77% compared with 63% without setup correction. An automated three-dimensional method further improved the frequency to 96%. Patient displacements in the SBF were generally small (< or = 2 mm, 1 standard deviation), but large craniocaudal displacements (maximal 7.2 mm) were occasionally observed.
CONCLUSION: Daily, CT-assisted patient setup may substantially improve tumor coverage, especially with the automated three-dimensional procedure. In the present treatment design, patient stability in the SBF should be verified with portal imaging.

Entities:  

Mesh:

Year:  2007        PMID: 17448881     DOI: 10.1016/j.ijrobp.2006.12.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Adaptive management of liver cancer radiotherapy.

Authors:  Kristy K Brock; Laura A Dawson
Journal:  Semin Radiat Oncol       Date:  2010-04       Impact factor: 5.934

2.  Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy.

Authors:  Alejandra Méndez Romero; Fatma Keskin-Cambay; Rob M van Os; Joost J Nuyttens; Ben J M Heijmen; Jan N M IJzermans; Cornelis Verhoef
Journal:  Rep Pract Oncol Radiother       Date:  2016-12-02

3.  Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results.

Authors:  Carmen Llacer-Moscardo; Olivier Riou; David Azria; Ludovic Bedos; Norbert Ailleres; Francois Quenet; Philippe Rouanet; Marc Ychou; Pascal Fenoglietto
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-05

4.  Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance.

Authors:  Gye Won Choi; Yelin Suh; Prajnan Das; Joseph Herman; Emma Holliday; Eugene Koay; Albert C Koong; Sunil Krishnan; Bruce D Minsky; Grace L Smith; Cullen M Taniguchi; Sam Beddar
Journal:  Radiat Oncol       Date:  2019-08-30       Impact factor: 3.481

5.  The analysis of respiration-induced pancreatic tumor motion based on reference measurement.

Authors:  Lukas Knybel; Jakub Cvek; Bretislav Otahal; Tomas Jonszta; Lukas Molenda; Daniel Czerny; Eva Skacelikova; Marian Rybar; Pavel Dvorak; David Feltl
Journal:  Radiat Oncol       Date:  2014-08-30       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.